SPTX NASDAQ
Credit Risk of going bust: not rated Debt: 0.4% of company value Bonds: none of note held by US funds details ▾
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Boston, MA 02210-2186
US
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| PureTech Health plc | C-Conversion | 965,255 | — | 2026-05-04 |
| PureTech Health plc | C-Conversion | 2,681,265 | — | 2026-05-04 |
| PureTech Health plc | C-Conversion | 12,736,014 | — | 2026-05-04 |
| PureTech Health plc | C-Conversion | 3,031,578 | — | 2026-05-04 |
| PureTech Health plc | C-Conversion | 40,000,000 | — | 2026-05-04 |